May 30 |
Russell 3000: Inovio, Ocugen among healthcare additions; Assertio, Ginkgo Bioworks among deletions
|
May 26 |
Verastem: A Shocking Drop On 'Positive' Data (Maintain Buy)
|
May 26 |
Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade
|
May 24 |
Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
|
May 24 |
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
|
May 24 |
Sector Update: Health Care Stocks Advance Pre-Bell Friday
|
May 24 |
ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success
|
May 24 |
Verastem whipsaws after updates for cancer drug combo
|
May 24 |
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
|
May 24 |
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
|